Particle therapy for cancers: a new weapon in radiation therapy

Abstract

Particle irradiation started to draw attention in the past decade and has now become a hotspot in the radiation oncology community. This article reviews the most advanced developments in particle irradiation, focusing on the characteristics of proton and carbon ions in radiation physics and radiobiology. The Bragg peak of physical dose distribution causes proton and carbon beams to optimally meet the requirement for cancer irradiation because the Bragg peak permits the accurate concentration of the dose on the tumor, thus sparing the adjacent normal tissues. Moreover, carbon ion has more radiobiological benefits than photon and proton beams. These benefits include stronger sterilization effects on intrinsic radio-resistant tumors and more effective killing of hypoxic, G₀, and S phase cells. Compared with the most advanced radiation techniques using photon, such as three-dimensional conformal radiation therapy and intensity-modulated radiation therapy, proton therapy has yielded more promising outcomes in local control and survival for head and neck cancers, prostate carcinoma, and pediatric cancers. Carbon therapy in Japan showed even more promising results than proton therapy. The local controls and overall survivals were as good as that treated by surgery in early stages of non-small cell lung cancer, hepatocellular carcinoma, prostate carcinoma, and head and neck cancers, especially for such highly resistant tumors as melanoma. The non-invasive nature of particle therapy affords more patients with chances to receive and benefit from treatment. Particle therapy is gradually getting attention from the oncology community. However, the cost of particle therapy facilities has limited the worldwide use of this technology.

Keywords

radiation therapy / particle therapy / proton / carbon / cancer

References

[1] Slater JM, Archambeau JO, Miller DW, Notarus MI, Preston W, Slater JD. The proton treatment center at Loma Linda University Medical Center: rationale for and description of its development. Int J Radiat Oncol Biol Phys 1992; 22(2): 383-389

[2] Tsujii T, Kamada T, Baba M, Tsuji H, Kato H, Kato S, Yamada S, Yasuda S, Yanagi T, Kato H, Hara R, Yamamoto N, Mizoe J. Hirotoshi Kato, Shingo Kato, Shigeru Yamada, Shigeo Yasuda, Yanagi T, Kato H, Hara R, Yamamoto N, Mizoe J. Clinical advantages of carbon-ion radiotherapy. N J Phys 2008; 10(7): 075009

[3] Suit HD, Chu W. History of charged particle radiotherapy. In: DeLaney TF, Kooy HM. Proton and Charged Particle Radiotherapy. Wolter Kluwer, Lippincoot Williams and Wilkins, 2008:1-7

[4] Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65(4): 1087-1096

[5] Gerwech L, Paganetti H. Radiobiology of charged particles. In: DeLaney TF,Kooy HM. Proton and Charged Particle Radiotherapy. Wolter Kluwer, Lippincoot Williams and Wilkins, 2008:8-17

[6] Fokas E, Kraft G, An H, Engenhart-Cabillic R.Ion beam radiobiology and cancer: time to update ourselves. Biochimica et Biophysica Acta 2009;1796:216-229

[7] Allen C, Borak TB, Tsujii H, Nickoloff JA. Heavy charged particle radiobiology: using enhanced biological effectiveness and improved beam focusing to advance cancer therapy. Mutat Res 2011; 711(1-2): 150-157

[8] Joiner MC. Linear energy transfer and relative biological effectiveness. In: Joiner M, van der Kogel A. Basic clinical radiobiology .4th ed. Hodder Arnold, 2009:168-177

[9] Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 2004; 126(4): 1198-1203

[10] Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65(1): 107-111

[11] Iwata H, Murakami M, Demizu Y, Miyawaki D, Terashima K, Niwa Y, Mima M, Akagi T, Hishikawa Y, Shibamoto Y. High-dose proton therapy and carbon-ion therapy for stage I non-small cell lung cancer. Cancer 2010; 116(10): 2476-2485

[12] Nakayama H, Satoh H, Sugahara S, Kurishima K, Tsuboi K, Sakurai H, Ishikawa S, Tokuuye K. Proton beam therapy of Stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81(4):979-984

[13] Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for non-small cell lung cancer. Cancer 2011; 117(13): 3004-3013

[14] Slater JD, Yonemoto LT, Rossi CJ Jr, Reyes-Molyneux NJ, Bush DA, Antoine JE, Loredo LN, Schulte RW, Teichman SL, Slater JM. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 1998; 42(2): 299-304

[15] Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, Slater JM. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004; 59(2): 348-352

[16] Igaki H, Tokuuye K, Okumura T, Sugahara S, Kagei K, Hata M, Ohara K, Hashimoto T, Tsuboi K, Takano S, Matsumura A, Akine Y. Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 2004; 60(4): 1120-1126

[17] Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005; 23(9): 1839-1846

[18] Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, Shoda J, Hata M, Abei M, Igaki H, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005; 11(10): 3799-3805

[19] Carr BI, Nagalla S. Medical therapy for HCC. In: Carr BI. Hepatocellular Carcinoma. 2 ed. New York: Humana Press, 2009:551-554

[20] Proceedings of Int Sym Heavy Ion Therapy. <month>Jan</month><day>8</day>-<day>9</day>, 2011, Tokyo, Japan

[21] Gorenstein LA, Sonett JR. The surgical management of stage I and stage II lung cancer. Surg Oncol Clin N Am 2011; 20(4): 701-720

[22] Miyamoto T, Baba M, Yamamoto N, Koto M, Sugawara T, Yashiro T, Kadono K, Ezawa H, Tsujii H, Mizoe JE, Yoshikawa K, Kandatsu S, Fujisawa T; Working Group for Lung Cancer.Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007; 67(3): 750-758

[23] Miyamoto T, Baba M, Sugane T, Nakajima M, Yashiro T, Kagei K, Hirasawa N, Sugawara T, Yamamoto N, Koto M, Ezawa H, Kadono K, Tsujii H, Mizoe JE, Yoshikawa K, Kandatsu S, Fujisawa T; Working Group for Lung Cancer. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2007; 2(10): 916-926

[24] Earl TM, Chapman WC. Conventional surgical treatment ofβhepatocellular carcinoma. Clin Liver Dis 2011; 15(2): 353-370, vii-x

[25] Kato H, Tsujii H, Miyamoto T, Mizoe JE, Kamada T, Tsuji H, Yamada S, Kandatsu S, Yoshikawa K, Obata T, Ezawa H, Morita S, Tomizawa M, Morimoto N, Fujita J, Ohto M; Liver Cancer Working Group. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004; 59(5): 14681476

[26] Tsujii H, Mizoe J, Kamada T, Baba M, Tsuji H, Kato H, Kato S, Yamada S, Yasuda S, Ohno T, Yanagi T, Imai R, Kagei K, Hara R, Hasegawa A, Nakajima M, Sugane N, Tamaki N, Takagi R, Kandatsu S, Yoshikawa K, Kishimoto R, Miyamoto T. Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res (Tokyo) 2007; 48 (Suppl A):A1A13

[27] Mizoe JE, Tsujii H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y, Hasegawa A, Yamamoto N, Ebihara S, Konno A. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 60(2): 358364

[28] Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jäkel O, Edler L, Scholz M, Debus J. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007; 68(2): 449457

[29] Imai R, Kamada T, Tsuji H, Yanagi T, Baba M, Miyamoto T, Kato S, Kandatsu S, Mizoe JE, Tsujii H, Tatezaki S. Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res 2004; 10(17): 57415746

[30] Kamada T, Tsujii H, Tsuji H, Yanagi T, Mizoe JE, Miyamoto T, Kato H, Yamada S, Morita S, Yoshikawa K, Kandatsu S, Tateishi A. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol 2002; 20(22): 44664471

[32] Brada M, Pijls-Johannesma M, De Ruysscher D. Current clinical evidence for proton therapy. Cancer J 2009; 15(4): 319324

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg